Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2007 Jan 9:3:1.
doi: 10.1186/1860-5397-3-1.

8-epi-Salvinorin B: crystal structure and affinity at the kappa opioid receptor

Affiliations

8-epi-Salvinorin B: crystal structure and affinity at the kappa opioid receptor

Thomas A Munro et al. Beilstein J Org Chem. .

Abstract

There have been many reports of epimerization of salvinorins at C-8 under basic conditions, but little evidence has been presented to establish the structure of these compounds. We report here the first crystal structure of an 8-epi-salvinorin or derivative: the title compound, 2b. The lactone adopts a boat conformation with the furan equatorial. Several lines of evidence suggest that epimerization proceeds via enolization of the lactone rather than a previously proposed indirect mechanism. Consistent with the general trend in related compounds, the title compound showed lower affinity at the kappa opioid receptor than the natural epimer salvinorin B (2a). The related 8-epi-acid 4b showed no affinity.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Stereoview of the molecular structure of 2b, showing 50% probability displacement ellipsoids and the atom-numbering scheme. Only one of the two molecules in the asymmetric unit is shown.
Figure 2
Figure 2
Stereoview of the packing of 2b. H atoms are not shown.
Scheme 1
Scheme 1
Koreeda et al's proposed mechanism for the epimerization.

Similar articles

Cited by

References

    1. Ortega A, Blount J F, Manchand P S. J Chem Soc, Perkin Trans 1. 1982:2505–2508. doi: 10.1039/p19820002505. - DOI
    1. Roth B L, Baner K, Westkaemper R, Siebert D, Rice K C, Steinberg S, Ernsberger P, Rothman R B. Proc Natl Acad Sci U S A. 2002;99:11934–11939. doi: 10.1073/pnas.182234399. - DOI - PMC - PubMed
    1. Beardsley P M, Howard J L, Shelton K L, Carroll F I. Psychopharmacology (Berlin) 2005;183:118–26. doi: 10.1007/s00213-005-0167-4. - DOI - PubMed
    1. Carlezon W A, Jr, Béguin C, DiNieri J A, Baumann M H, Richards M R, Todtenkopf M S, Rothman R B, Ma Z, Lee D Y, Cohen B M. J Pharmacol Exp Ther. 2006;316:440–7. doi: 10.1124/jpet.105.092304. - DOI - PubMed
    1. Mague S D, Pliakas A M, Todtenkopf M S, Tomasiewicz H C, Zhang Y, Stevens W C, Jr, Jones R M, Portoghese P S, Carlezon W A., Jr J Pharmacol Exp Ther. 2003;305:323–30. doi: 10.1124/jpet.102.046433. - DOI - PubMed

LinkOut - more resources